Physician profile
Ariana Brown
NPI 1811560170
$4,390.53
in general payments reported to CMS, 2019-2025
21 companies · $490 in 2025
The $490 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.32 · 2022: $1,223 · 2023: $1,242 · 2024: $1,421 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,150 · Travel and Lodging: $2.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,150.20 |
| Travel and Lodging | $2.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $737.46 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $643.74 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $600.33 | 2022-2024 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $459.32 | 2024-2025 | |
| Novo Nordisk INC | $313.98 | 2022-2024 | |
| Glaxosmithkline, LLC. | $258.09 | 2022-2023 | Shingrix |
| Abbott Laboratories | $227.49 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $125.00 | 2024 | Veozah |
| Gilead Sciences, INC. | $124.31 | 2023 | Descovy |
| Amgen INC. | $122.06 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.58 | 2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $113.33 | 2023 | Rexulti |
| Axsome Therapeutics, INC. | $112.95 | 2024 | Auvelity |
| Alkermes, INC. | $112.14 | 2024 | Vivitrol |
| Idorsia Pharmaceuticals US INC | $106.84 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $100.00 | 2022 | |
| Csl Behring | $46.70 | 2024 | Kcentra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.11 | 2023 | Xifaxan, Trulance |
| Hologic Sales and Service, LLC | $19.94 | 2022 | |
| Merck Sharp & Dohme LLC | $16.20 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ariana Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.